Image

Global Vaccine Production Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Vaccine Production Market, By Classification (Adult Vaccine Production, Pediatric Vaccine Production), Disease Type (Hepatitis B, Malaria, Yellow Fever, Typhoid, Rabies, HIV, Cancer, Influenza, West Nile, Japanese Encephalitis, Pneumococcal, Rotavirus, DTP, Polio, Varicella, Meningococcal, Measles, Mumps, and Rubella, Tuberculosis)– Industry Trends and Forecast to 2029

Vaccine Production Market

Market Analysis and Size

Vaccines, often known as immunizations, are injections of a disease's weakened form into a person's body to cause the body to produce antibodies or immunity against the disease. A number of diseases with significant mortality rates, such as polio and smallpox, have been eradicated thanks to effective immunisation. Vaccinations are used in various regional disease-prevention programmes since they serve such an important role in maintaining people's long-term health in different countries. The demand for immunizations has risen in recent years as viral and bacterial infectious illnesses have increased. Vaccinations are primarily given to people of all ages to boost their immune systems and provide protection against various infectious diseases throughout their lives.

Data Bridge Market Research analyses that the vaccine production market which was USD 44.40 billion in 2021, would rocket up to USD 77.73 billion by 2029, and is expected to undergo a CAGR of 7.25% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation                       

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Classification (Adult Vaccine Production, Pediatric Vaccine Production), Disease Type (Hepatitis B, Malaria, Yellow Fever, Typhoid, Rabies, HIV, Cancer, Influenza, West Nile, Japanese Encephalitis, Pneumococcal, Rotavirus, DTP, Polio, Varicella, Meningococcal, Measles, Mumps, and Rubella, Tuberculosis)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Sanofi (France), Valneva SE (France), CSL Limited (Australia), GlaxoSmithKline plc. (U.K), MassBiologics (U.S), Johnson & Johnson Private Limited (U.S), AstraZeneca (U.K), Pfizer Inc. (U.S), Merck KGaA (Germany), Novartis AG (Switzerland), BAXTER (U.S), Teva Pharmaceutical Industries Ltd. (Israel), IDT Biologika (U.S), Thermo Fisher Scientific Inc. (U.S), Lonza (Switzerland), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S), Charles River Laboratories (U.S)

Market Opportunities

  • Rising prevalence of infectious diseases
  •  Increasing government funding for vaccine production, and growing emphasis on immunization

Market Definition

A vaccine is a biological product created by combining chemical drugs with disease-causing microorganisms in weakened form. It acts as antigens in disease prevention and stimulates the production of antibodies against a variety of pathogens when injected into the human body. Before receiving clinical approval, vaccines are rigorously studied to verify that they are both safe and effective in nature. They are commonly used to prevent polio, measles, influenza, tetanus, diphtheria, meningitis, and hepatitis, among other life-threatening infections. As a result, they are increasingly being utilised in clinics, hospitals, and vaccination centres for immunisation processes and research and development (R & R&D) in clinical laboratories and research institutes.

Vaccine Production Market Dynamics

Drivers

  • Surging levels of growth

Increased investment in the development of technologically advanced products, the prevalence of WHO and GAVI (global alliance for vaccines and immunisation), rising government support, and rising occurrences of infectious diseases will likely accelerate vaccine production growth in the forecast period of 2022-2029 among developing economies. On the other hand, the increased focus on therapeutic vaccines will promote numerous chances, resulting in the expansion of the vaccine production market over the projection period.

  • Applications of vaccine production

The global market is being driven by the increased occurrence of infectious diseases around the world. This is supported by rising public awareness of the necessity of effective vaccination in eradicating these diseases, resulting in a significant increase in vaccine demand. A number of non-profit operations aiming at boosting public knowledge about the importance of immunisation, particularly in endemic and rural areas, have an impact on the market. Many governments are also launching various free vaccination programmes in an effort to encourage individuals to be vaccinated, resulting in a positive market outlook.

  • Increase in vaccine development

The worldwide vaccine production market is likely to be driven by increased expenditure in the discovery of novel vaccines. For example, Scripps Research Florida researchers have developed a non-traditional vaccine to combat the SIVmac239 virus strain known as the "death star." The researchers' non-traditional vaccination gives long-term protection against numerous types of HIV in healthy people, increasing demand for the vaccine. Furthermore, the rising frequency of numerous infectious diseases and increased knowledge about early disease diagnosis and prevention are driving demand for protective vaccinations, increasing market growth.

Opportunities

By 2024, the global COVID-19 vaccine production market is estimated to exceed USD 5 billion. The market is predicted to increase due to the constant focus of government agencies and various vaccine producers around the world on preventing human and economic losses due to the COVID-19 virus. The availability of vaccination doses across the globe is projected to increase during the projection period, with some suppliers applying novel techniques such as integrating the phase 1 and 2 clinical trial stages and obtaining faster regulatory clearances from health agencies.

Furthermore, pharmaceutical companies are emphasising COVID-19-related diagnostics, therapies, health technologies, and vaccinations, as well as evaluating the efficacy of existing treatments. All of these factors are expected to have an impact on the global vaccine manufacturing market in the future.

Restraints/Challenges

Vaccine supply might be stifled by high storage and shipping costs. These factors are expected to hamper the revenue growth of the vaccines market to a certain extent going ahead.

This vaccine production market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the vaccine production market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid impact on Vaccine Production

The COVID-19 virus has recently infected millions of people throughout the world. In some areas, community transmission has resulted in an increase in mortality. Biopharmaceutical and biotech firms succeeded in bringing an effective vaccine against the virus that causes SARS-Cov-2 to market in 2021. The coronavirus outbreak has spurred extraordinary demand, and firms and the government are both investing extensively in research and development to meet the rising demand for COVID-19 vaccines. This is projected to improve the market's prospects for growth.

Global Vaccine Production Market Scope

The vaccine production market is segmented on the basis of classification and disease type. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Classification

  • Adult Vaccine Production
  • Pediatric Vaccine Production

Disease Type

  • Hepatitis B
  • Malaria
  • Yellow Fever
  • Typhoid
  • Rabies
  • HIV
  • Cancer
  • Influenza
  • West Nile
  • Japanese Encephalitis
  • Pneumococcal
  • Rotavirus
  • DTP
  • Polio
  • Varicella
  • Meningococcal
  • Measles
  • Mumps
  • Rubella
  • Tuberculosis

Vaccine Production Market Regional Analysis/Insights

The vaccine production market is analysed and market size insights and trends are provided by country, classification and disease type as referenced above.

The countries covered in the vaccine production market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the vaccine production market, attributed to enlarged public awareness of the risks of infectious diseases and increased government and non-government expenditures on vaccine production and widespread distribution.

Asia-Pacific is expected to fastest growth over the forecast period of 2022-2029 due to increasing target population base with high unmet clinical needs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Vaccine Production Market Share Analysis

The vaccine production market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to vaccine production market.

Some of the major players operating in the vaccine production market are:

  • Sanofi (France)
  • Valneva SE (France)
  • CSL Limited (Australia)
  • GlaxoSmithKline plc. (U.K)
  • MassBiologics (U.S)
  • Johnson & Johnson Private Limited (U.S)
  • AstraZeneca (U.K)
  • Pfizer Inc. (U.S)
  • Merck KGaA (Germany)
  • Novartis AG (Switzerland)
  • BAXTER (U.S)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • IDT Biologika (U.S)
  • Thermo Fisher Scientific Inc. (U.S)
  • Lonza (Switzerland)
  • Boehringer Ingelheim International GmbH (Germany)
  • Catalent, Inc (U.S)
  • Charles River Laboratories (U.S)


SKU-
Why Choose Us


Frequently Asked Questions

The vaccine production market value is expected USD 77.73 billion by 2029.
The vaccine production market is projected to grow at a CAGR of 7.25% during the forecast period of 2022-2029.
The major players operating in the Vaccine Production Market are Sanofi (France), Valneva SE (France), CSL Limited (Australia), GlaxoSmithKline plc. (U.K), MassBiologics (U.S), Johnson & Johnson Private Limited (U.S), AstraZeneca (U.K), Pfizer Inc. (U.S), Merck KGaA (Germany), Novartis AG (Switzerland), BAXTER (U.S), Teva Pharmaceutical Industries Ltd. (Israel), IDT Biologika (U.S), Thermo Fisher Scientific Inc. (U.S), Lonza (Switzerland), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S), Charles River Laboratories (U.S).
The major countries covered in the Vaccine Production Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.